Milind Deshpande

Achillion Pharmaceuticals

Former Director and Chief Executive Officer

Overview

Milind Deshpande made an average of $2M in compensation at Achillion Pharmaceuticals from 2008 to 2018.

Annual data

2018

In 2018, Milind Deshpande earned a total compensation of $2.1M as Former Director and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking3,556 out of 8,301
Percentile57.2%

Milind Deshpande's 2018 compensation ranked 3,556th out of 8,301 executive pay records tracked by us this year.

Deshpande earned more than 57.2% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking211 out of 542
Percentile61.1%

In the industry group of Drugs, Deshpande's pay ranked 211th out of 542 executive pay records tracked by us in 2018.

Deshpande earned more than 61.1% of executives in this group.

Option Awards$1,295,616
Salary$227,888
Other$545,959
Total$2,069,463

Deshpande received $1.3M in option awards, which accounts for 62.61% of total compensation.

Deshpande also received $227.9K in salary and $546K in other compensation.

2017

In 2017, Milind Deshpande earned a total compensation of $2.2M as Former Director and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking4,602 out of 13,165
Percentile65.0%

Milind Deshpande's 2017 compensation ranked 4,602nd out of 13,165 executive pay records tracked by us this year.

Deshpande earned more than 65.0% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking336 out of 1,395
Percentile75.9%

In the industry group of Drugs, Deshpande's pay ranked 336th out of 1,395 executive pay records tracked by us in 2017.

Deshpande earned more than 75.9% of executives in this group.

Non-Equity Incentive Plan$260,703
Option Awards$1,335,258
Salary$607,700
Other$8,557
Total$2,212,218

Deshpande received $1.3M in option awards, which accounts for 60.36% of total compensation.

Deshpande also received $260.7K in non-equity incentive plan, $607.7K in salary and $8.6K in other compensation.

2016

In 2016, Milind Deshpande earned a total compensation of $3M as Director, President and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking3,186 out of 13,853
Percentile77.0%

Milind Deshpande's 2016 compensation ranked 3,186th out of 13,853 executive pay records tracked by us this year.

Deshpande earned more than 77.0% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking227 out of 1,472
Percentile84.6%

In the industry group of Drugs, Deshpande's pay ranked 227th out of 1,472 executive pay records tracked by us in 2016.

Deshpande earned more than 84.6% of executives in this group.

Non-Equity Incentive Plan$218,144
Option Awards$2,153,727
Salary$590,000
Other$8,310
Total$2,970,181

Deshpande received $2.2M in option awards, which accounts for 72.51% of total compensation.

Deshpande also received $218.1K in non-equity incentive plan, $590K in salary and $8.3K in other compensation.

2015

In 2015, Milind Deshpande earned a total compensation of $950.1K as Director, President and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking8,191 out of 13,574
Percentile39.7%

Milind Deshpande's 2015 compensation ranked 8,191st out of 13,574 executive pay records tracked by us this year.

Deshpande earned more than 39.7% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking896 out of 1,484
Percentile39.6%

In the industry group of Drugs, Deshpande's pay ranked 896th out of 1,484 executive pay records tracked by us in 2015.

Deshpande earned more than 39.6% of executives in this group.

Non-Equity Incentive Plan$416,667
Salary$525,100
Other$8,298
Total$950,065

Deshpande received $525.1K in salary, which accounts for 55.27% of total compensation.

Deshpande also received $416.7K in non-equity incentive plan and $8.3K in other compensation.

2014

In 2014, Milind Deshpande earned a total compensation of $4.9M as Director, President and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking1,582 out of 12,876
Percentile87.7%

Milind Deshpande's 2014 compensation ranked 1,582nd out of 12,876 executive pay records tracked by us this year.

Deshpande earned more than 87.7% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking138 out of 1,310
Percentile89.5%

In the industry group of Drugs, Deshpande's pay ranked 138th out of 1,310 executive pay records tracked by us in 2014.

Deshpande earned more than 89.5% of executives in this group.

Non-Equity Incentive Plan$384,860
Option Awards$4,070,653
Salary$484,100
Other$8,124
Total$4,947,737

Deshpande received $4.1M in option awards, which accounts for 82.27% of total compensation.

Deshpande also received $384.9K in non-equity incentive plan, $484.1K in salary and $8.1K in other compensation.

2013

In 2013, Milind Deshpande earned a total compensation of $4.3M as Director, President and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking1,564 out of 11,965
Percentile86.9%

Milind Deshpande's 2013 compensation ranked 1,564th out of 11,965 executive pay records tracked by us this year.

Deshpande earned more than 86.9% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking93 out of 1,095
Percentile91.5%

In the industry group of Drugs, Deshpande's pay ranked 93rd out of 1,095 executive pay records tracked by us in 2013.

Deshpande earned more than 91.5% of executives in this group.

Non-Equity Incentive Plan$148,893
Option Awards$3,679,998
Salary$435,583
Other$7,992
Total$4,272,466

Deshpande received $3.7M in option awards, which accounts for 86.13% of total compensation.

Deshpande also received $148.9K in non-equity incentive plan, $435.6K in salary and $8K in other compensation.

2012

In 2012, Milind Deshpande earned a total compensation of $1.5M as Director, President and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking4,441 out of 10,949
Percentile59.4%

Milind Deshpande's 2012 compensation ranked 4,441st out of 10,949 executive pay records tracked by us this year.

Deshpande earned more than 59.4% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking220 out of 850
Percentile74.1%

In the industry group of Drugs, Deshpande's pay ranked 220th out of 850 executive pay records tracked by us in 2012.

Deshpande earned more than 74.1% of executives in this group.

Non-Equity Incentive Plan$201,272
Option Awards$922,084
Salary$376,100
Other$7,833
Total$1,507,289

Deshpande received $922.1K in option awards, which accounts for 61.17% of total compensation.

Deshpande also received $201.3K in non-equity incentive plan, $376.1K in salary and $7.8K in other compensation.

2011

In 2011, Milind Deshpande earned a total compensation of $1.1M as Director, President and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking5,200 out of 10,035
Percentile48.2%

Milind Deshpande's 2011 compensation ranked 5,200th out of 10,035 executive pay records tracked by us this year.

Deshpande earned more than 48.2% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking257 out of 705
Percentile63.5%

In the industry group of Drugs, Deshpande's pay ranked 257th out of 705 executive pay records tracked by us in 2011.

Deshpande earned more than 63.5% of executives in this group.

Non-Equity Incentive Plan$144,536
Option Awards$555,511
Salary$359,975
Other$7,703
Total$1,067,725

Deshpande received $555.5K in option awards, which accounts for 52.03% of total compensation.

Deshpande also received $144.5K in non-equity incentive plan, $360K in salary and $7.7K in other compensation.

2010

In 2010, Milind Deshpande earned a total compensation of $907.1K as President, Research and Development and Chief Scientific Officer at Achillion Pharmaceuticals.

Ranking5,321 out of 9,477
Percentile43.9%

Milind Deshpande's 2010 compensation ranked 5,321st out of 9,477 executive pay records tracked by us this year.

Deshpande earned more than 43.9% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking257 out of 619
Percentile58.5%

In the industry group of Drugs, Deshpande's pay ranked 257th out of 619 executive pay records tracked by us in 2010.

Deshpande earned more than 58.5% of executives in this group.

Non-Equity Incentive Plan$116,000
Option Awards$454,000
Salary$329,436
Other$7,673
Total$907,109

Deshpande received $454K in option awards, which accounts for 50.05% of total compensation.

Deshpande also received $116K in non-equity incentive plan, $329.4K in salary and $7.7K in other compensation.

2009

In 2009, Milind Deshpande earned a total compensation of $540K as President, Research and Development and Chief Scientific Officer at Achillion Pharmaceuticals.

Ranking5,992 out of 8,703
Percentile31.2%

Milind Deshpande's 2009 compensation ranked 5,992nd out of 8,703 executive pay records tracked by us this year.

Deshpande earned more than 31.2% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking347 out of 583
Percentile40.5%

In the industry group of Drugs, Deshpande's pay ranked 347th out of 583 executive pay records tracked by us in 2009.

Deshpande earned more than 40.5% of executives in this group.

Non-Equity Incentive Plan$90,957
Option Awards$141,000
Salary$303,190
Other$4,841
Total$539,988

Deshpande received $303.2K in salary, which accounts for 56.15% of total compensation.

Deshpande also received $91K in non-equity incentive plan, $141K in option awards and $4.8K in other compensation.

2008

In 2008, Milind Deshpande earned a total compensation of $410.3K as President, Research and Development and Chief Scientific Officer at Achillion Pharmaceuticals.

Ranking6,165 out of 7,730
Percentile20.2%

Milind Deshpande's 2008 compensation ranked 6,165th out of 7,730 executive pay records tracked by us this year.

Deshpande earned more than 20.2% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking398 out of 542
Percentile26.6%

In the industry group of Drugs, Deshpande's pay ranked 398th out of 542 executive pay records tracked by us in 2008.

Deshpande earned more than 26.6% of executives in this group.

Non-Equity Incentive Plan$51,975
Option Awards$61,357
Salary$288,000
Other$8,921
Total$410,253

Deshpande received $288K in salary, which accounts for 70.20% of total compensation.

Deshpande also received $52K in non-equity incentive plan, $61.4K in option awards and $8.9K in other compensation.